Neil Sheppard
Joern-Peter Halle
Peter is leading the Translational Innovation Platform Immuno-Oncology with global responsibility for the research, discovery, and translational aspects of Merck KGaA’s IO portfolio. As the global head for External Innovation he oversees the search & evaluation of external opportunities in all therapeutic areas ranging from academic collaborations to clinical assets. He is also responsible for innovation initiatives of the healthcare business and a member of the investment committee of Merck Venture, Merck KGaA’s corporate VC. He started his carrier in Merck KGaA 12 years ago as a member of the corporate development. Prior to joining Merck KGaA, he co-founded a biotech company focusing on R&D in dermatology where he was responsible for IP, bioinformatics, and technology development and served as a Chief Business Officer.
Laurence Cooper
Michael Poisel
Gary Sclar
Ronald Dudek
James Noble
Karim Helmy
Stefan Jennewein
Dr. Stefan Jennewein studied Biochemistry, Pharmacology and Organic Chemistry at the Universities of Sussex (Brighton, UK), Zurich (CH), Tübingen (D) and Cambridge (UK), and at the Ludwig-Maximilians-Universität (Munich, D), where he obtained a PhD. He also gained practical experience through his work at Washington State University (Pullman, USA), the company DSM N.V. (Delft, NL), the Technical University of Darmstadt (D), and the Fraunhofer Institute for Molecular Biology and Applied Ecology (Aachen, D) as the Head of the Department of Industrial Biotechnology. Dr. Stefan Jennewein is the Founder & CEO of Jennewein Biotechnologie GmbH
